NISSAN
11.2.2020 18:50:08 CET | Business Wire | Press release
Nissan comes to the rescue of frazzled parents across Europe with a guilt-free solution for those who heavily rely on the magical effects of dream driving to gently lull their children to sleep.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200211005864/en/
Introducing, the Nissan LEAF Dream Drive – the world’s first zero-emission lullaby, dreamt up by Nissan engineers in collaboration with Sound Designer and Sleep Coach, Tom Middleton. This sleep album for babies mimics the peaceful sound frequencies of a humming combustion engine – trusted to put children to sleep, at no CO2 emission cost.
New research finds parents across Europe are frustratingly sleep-deprived. The majority of parents (65%), with a child aged two and under, is surviving on less than five hours of sleep a night, with 60%v admitting they resort to dream drivingvi their children to sleep and over half (57%) doing it at least once a week.
When looking at why parents put their faith in this method, Nissan discovered that 70%vii of parents put their trust in the power of the vehicle’s movement, when in fact it is the soothing sound frequencies of an internal combustion engine (ICE) that is the biggest contributor to a child falling asleep in the car.
According to expert, Paul Speed-Andrews, Noise and Vibration Development Manager at Nissan, “An EV like the Nissan LEAF is a better choice for dream driving; although we are aware that the quiet soundscape might not be as effective as ICE cars. Combustion engines transmit a sound frequency, a combination of white, pink and brown noise varied in tone – creating an orchestral soundscape that is especially soothing and comforting to children.”
Frequent dream driving in a combustion engine leads to an increase in carbon footprint; with parents emitting up to 70,000g of CO2 emissionsviii every year. However, 70% of European parents agree an EV would reduce their guilt around dream driving and want to become better environmental role models for their children.
To offer a solution, Nissan has collaborated with renowned Sound Designer and Sleep Coach, Tom Middleton, to create Nissan LEAF Dream Drive – the first zero-emission lullaby, the kryptonite album for angry babies, contains five, three-minute tracks that work in harmony with the advanced in-car technology available within the all-electric LEAF.
“Nissan’s zero-emission lullaby combines early auditory development research with creative strategy and is inspired by the audible and inaudible sounds of the Nissan LEAF,” says Sound Designer, Tom Middleton. “Together with Nissan, we are finding innovative, health and safety-conscious ways to apply functional sound within EVs that goes beyond the vehicle itself, effectively inspiring a new generation of purpose-driven, human-first car design and functionality.”
Tom Middleton added: “It is the world’s first collaboration with a car as featured artist. In addition to the combustion engine frequencies that only children can hear – which help lull them to sleep – every sound you can hear comes from building an orchestra of sounds and rhythms from interior and exterior recordings of the LEAF.”
Dream driving in a Nissan LEAF could also help make the experience more relaxing for parents. Zero exhaust emissions and the car’s e-Pedal functionality aid in a smoother ride, allowing seamless driving and braking with a single pedal.
In addition, ProPILOT Assist significantly reduces driver stress and makes dream driving at night more comfortable and safer. It helps parents maintain a steady speed, keep a safe distance away from other cars and ensure they stay in lane.
“The Nissan Dream Drive depicts the future of using sound and other sensory elements to improve people’s lives, bringing together multisensory science, immersive technologies and sound design to explore new wellness-led opportunities within mobility.,” said Ari Peralta, interdisciplinary researcher who helped provide research insight on the project. “Our first – the Nissan LEAF Dream Drive, crafted in collaboration with Nissan – is set to help sleep-deprived parents across Europe.”
Parents can connect their smartphone to their Nissan LEAF through Android Auto and Apple CarPlay, to enjoy the lullaby available on platforms like Apple Music, Spotify, SoundCloud, YouTube and Deezer.
Listen to the zero-emission lullaby on the following streaming platforms: https://lifetracks.lnk.to/NissanLEAFDreamDrive
Learn more about 100% Electric Nissan LEAF on: https://www.nissan.co.uk/vehicles/new-vehicles/leaf.html
### ENDS ###
About Nissan in Europe
Nissan has one of the most comprehensive European presences of any overseas manufacturer, employing more than 16,000 staff across locally based design, research & development, manufacturing, logistics and sales & marketing operations. In 2018, Nissan plants in the UK, Spain and Russia produced about 600,000 vehicles including award-winning crossovers, commercial vehicles and the Nissan LEAF, Europe’s most selling electric vehicle in 2018. Pursuing a goal of zero emissions and zero fatalities on the road, Nissan is leading the field with its vision of Intelligent Mobility. Designed to guide Nissan’s product and technology pipeline, this 360 degree approach to the future of mobility will anchor critical company decisions around how cars are powered, how cars are driven, and how cars integrate into society.
About Nissan Motor Co., Ltd.
Nissan is a global full-line vehicle manufacturer that sells more than 60 models under the Nissan, INFINITI and Datsun brands. In fiscal year 2018, the company sold 5.52 million vehicles globally, generating revenue of 11.6 trillion yen. Nissan’s global headquarters in Yokohama, Japan, manages operations in six regions: Asia & Oceania; Africa, the Middle East & India; China; Europe; Latin America; and North America. Nissan has partnered with French manufacturer Renault since 1999 and acquired a 34% stake in Mitsubishi Motors in 2016. The Renault-Nissan-Mitsubishi alliance sold 10.76 million vehicles combined in calendar year 2018.
For more information about our products, services and commitment to sustainable mobility, visit nissan-global.com . You can also follow us on Facebook , Instagram , Twitter and LinkedIn and see all our latest videos on YouTube .
i Consumer research conducted in November 2019 by Explain the Market and commissioned by Nissan of 7,500 consumers across England, France, Germany, Spain, Italy, Norway and the Netherlands.
ii Dream driving is traditionally a short journey in a car with a combustion engine which helps your child get to sleep.
iii Consumer research conducted in November 2019 by Explain the Market and commissioned by Nissan of 7,500 consumers across England, France, Germany, Spain, Italy, Norway and the Netherlands.
iv This was calculated on the assumption that vehicle travels at an average speed of 48kph per 15-minute dream drive, once a week:
- Average g/km for LEAF-sized, lower medium segment car: 111.5g/km
- Distance travelled in 1 minute, based on the above: 800 metres
- Grams of CO2 emitted in 1 minute, based on the above: 89.2g
-
Amount of CO2
emitted on average, with 780 minutes of dream driving per year: 69,576g (69.576kg)
- Based on 15 minutes of dream driving per week, as per the consumer research findings
v Consumer research conducted in November 2019 by Explain the Market and commissioned by Nissan of 7,500 consumers across England, France, Germany, Spain, Italy, Norway and the Netherlands.
vi Dream driving is traditionally a short journey in a car with a combustion engine which helps your child get to sleep.
vii Consumer research conducted in November 2019 by Explain the Market and commissioned by Nissan of 7,500 consumers across England, France, Germany, Spain, Italy, Norway and the Netherlands.
viii This was calculated on the assumption that vehicle travels at an average speed of 48kph per 15-minute dream drive, once a week:
- Average g/km for LEAF-sized, lower medium segment car: 111.5g/km
- Distance travelled in 1 minute, based on the above: 800 metres
- Grams of CO2 emitted in 1 minute, based on the above: 89.2g
-
Amount of CO2
emitted on average, with 780 minutes of dream driving per year: 69,576g (69.576kg)
- Based on 15 minutes of dream driving per week, as per the consumer research findings
Disclaimer: Whilst unlikely to cause drowsiness in adults, take care whilst driving. Don’t operate heavy machinery or listen to the track whilst submerged in water.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200211005864/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
